At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
MR-Guided Transurethral US Ablation of Prostate Tissuedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
In Brief
A clinical study evaluating MR-Guided Transurethral US Ablation of Prostate Tissue for Prostate Cancer. Completed, enrolled 30 participants across 3 sites in 3 countries.
Detailed Summary
This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada, Germany, United States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 2012
Enrollment StartMar 2013
Primary CompletionMar 2015
Study CompletionJun 2019
TodayJul 2026
First PostedSep 18, 2012
Enrollment StartMar 13, 2013
Primary CompletionMar 23, 2015
Study CompletionJun 11, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 13.8 years ago
Interventions
MR-Guided Transurethral US Ablation of Prostate Tissuedevice
The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.